Pliant Therapeutics (PLRX) Operating Expenses (2019 - 2026)

Pliant Therapeutics (PLRX) has 8 years of Operating Expenses data on file, last reported at $21.8 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $21.8 million, down 63.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $119.2 million (down 49.25% YoY), and the FY2025 annual result was $156.4 million, down 31.52% from the prior year.
• Operating Expenses eased to $21.8 million in Q1 2026 per PLRX's latest filing, from $23.6 million in the prior quarter.
• Over five years, Operating Expenses peaked at $62.0 million in Q3 2024 and troughed at $21.8 million in Q1 2026.
• A 5-year average of $42.9 million and a median of $45.6 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 48.0% in 2022, then plunged 63.06% in 2026.
• A 5-year view of Operating Expenses shows it stood at $39.4 million in 2022, then rose by 19.49% to $47.0 million in 2023, then climbed by 13.36% to $53.3 million in 2024, then tumbled by 55.78% to $23.6 million in 2025, then slipped by 7.66% to $21.8 million in 2026.
• Business Quant data shows PLRX's Operating Expenses at $21.8 million in Q1 2026, $23.6 million in Q4 2025, and $28.3 million in Q3 2025.